1606 Corporation (PK) (CBDW) Quote

$CBDW Exciting times ahead for customer service. At CBDWAI, we believe #AI is revolutionizing the customer experience. Here are six ways AI will shape the future:

- Personalized Training: Generative

- AI-Driven Personalization

- Generative AI Call Scripts

- Conversational AI Bots

- AI-Driven Insights

- Dynamic FAQs

https://lnkd.in/gjTZciZs

1606 Corp is transforming e-commerce with CBDWAI, our pioneering AI chatbot technology. With the AI market expected to soar to $2.25 trillion by 2030, investing in 1606 Corp offers a forward-thinking opportunity in the ever-changing digital arena.

#AI #CustomerService #CustomerExperience #chatcbdw #ai
#1606corp #investing #otc #stockinvesting CEO Austen Lambrecht #CBDWAI

Gotta pay all those pumpers somehow 

Keep an eye on the number of Outstanding Shares. The number has been increasing lately.
https://www.otcmarkets.com/stock/CBDW/security

Let's have a week $CBDW

Not really, not for a pumper. Another dull one. 

What about. 04's? 

$CBDW .017's going! @CBDWinc's robust IP portfolio serves multiple purposes: it enhances the company’s valuation, attracts potential partnerships and investments, and fosters an environment of continuous innovation. By protecting its proprietary technologies, CBDW can maintain a competitive edge, ensuring that its solutions remain unique and are not easily replicated by competitors. https://cbdw.ai/1606-corporation-cbdw-harnessing-competitive-advantage-through-expertise-industry-focus-and-intellectual-property/

Good Morning $CBDW

$CBDW Strong Buy .015 +5.63% HOD .016 5-Day Perf.+6.38%
www.cbdw.ai #AI #chatbots @cbdwinc

Good Morning $CBDW

With $CBDW's strategic investment in Adnexus Biotech, @CBDWInc has now entered the #AI drug discovery market.
https://cbdw.ai/the-role-of-ai-in-biotech-and-ai-driven-drug-discovery/ #Biotech #AIinHealthcare

$CBDW
$CBDW Looks like it found support and bounce underway..let’s see some momentum here.. pic.twitter.com/q5VtFonq1L— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) October 31, 2024

Stephen Popp / Gaurav Chandra / Tom Nelson scam 

Wow! That's amazing! 🤢 blech

$CBDW Founder Greg Lambrecht on LinkedIn: "Technology is driving the future of personalized medicine, where treatments are tailored to individual genetic profiles, leading to better outcomes and fewer adverse effects. The role of AI in biotech is paving the way for faster, more efficient drug development and groundbreaking advances in patient care."

#AIinHealthcare #Biotech #DrugDiscovery #PersonalizedMedicine #CBDW #HealthTech #FutureOfMedicine #AIDrivenSolutions #1606Corp #CBDWAI https://www.linkedin.com/posts/greg-lambrecht_aiinhealthcare-biotech-drugdiscovery-activity-7256741123769933824-s4UR?utm_source=share&utm_medium=member_desktop

Strategic Expansion of 1606 Corporation (CBDW) Through ISO Partnerships

1606 Corporation (CBDW) is poised for significant growth in the coming years, leveraging strategic partnerships to enhance its market presence and operational efficiency. As part of its expansion plan, CBDW aims to secure ten International Standards Organization (ISO) partnerships by the end of 2024. This initiative will focus on collaborating with web developers, investor relations (IR) firms, transfer agents, and press services, positioning the company to better serve its stakeholders and capitalize on emerging opportunities in the CBD and investor relations industries.

Read more here:
https://cbdw.ai/strategic-expansion-of-1606-corporation-cbdw-through-iso-partnerships/

This one stinks of Gaurav Chandra's body odor.  Total scam! 

No, it moves slow. Slowly down each day. Further and further from your 4 cents

This one moves fast. $CBDW

What a POS scam. Nothing but downward action for last month. 

Pure scam from Gaurav Chandra of ENZC 

Good Morning $CBDW

Is this the bottom? Is it going to move up from here?

Focus is scamming with Gaurav Chandra

$CBDW Business Plan: Our focus is on signing business to use the chatbot with a monthly recuring licensing fee model. We are using a combination of our website, online ads, and email campaigns targeted towards CBD brands and retailers, we have cultivated considerable interest in 1606 and our AI Chatbot technology.

We are also using ISO’s or independent sales organizations to sell the Chatbot or include it in a package deal with their products. These ISO’s include but are not limited to CBD Distributors, website designers and builders, and payment processing services within and outside the CBD industry.

Wrong!

Sure looks like it on the chart...

Is this the bottom? Is it going move up from here?

When is the rebound supposed to happen? Also, wen Lambo? What should I name my Yacht?

$CBDW ~ CBDWAI's ambitious target of establishing 10 "ISO partnerships" underscores its commitment to creating a robust operational framework. By aligning with ISO-certified organizations, CBDW can ensure that its processes and products meet internationally recognized standards. https://cbdw.ai/strategic-expansion-of-1606-corporation-cbdw-through-iso-partnerships/

Dirtbag Tom Nelson and his 100 bot accounts are the only pumpers left here.  

At least when it goes to trips, it will be worth day-trading for a while.

Never has, according to current-day listings and filings. And Chandra better be careful, two of his partners on his partners page have gone almost extinct, but still posted on his new website. If you falsely advertise that you've been given an ISO certification, or have an ISO-compliant product & process, that takes some money and time to do, and yes, I know Chandra has the money from 'somewhere' to do it, you can get into very serious trouble, in any country.

AI Scam

$CBDW Tweet out! "Take a look at the new blog on the competitive advantages cbdw has." Take a look at the new blog on the competitive advantages cbdw has.https://t.co/tbrlsHAmCn— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) October 28, 2024 https://t.co/tbrlsHAmCn

$CBDW - "Take a look at the new blog on the competitive advantages cbdw has."

Take a look at the new blog on the competitive advantages cbdw has.https://t.co/tbrlsHAmCn— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) October 28, 2024

IF, Chandra and the Cotropias finally come through, after 8-10 years of abject failure at ENZC, then CBDW may have something tangible enough to raise the PPS. Otherwise, this stock will wallow in the low pennies at best.

Gaurav Chandra scam.  

$CBDW 1606 Corporation (CBDW): Harnessing Competitive Advantage Through Expertise, Industry Focus, and Intellectual Property https://cbdw.ai/1606-corporation-cbdw-harnessing-competitive-advantage-through-expertise-industry-focus-and-intellectual-property/ http://cbdw.ai #blog #AI #chatbots

Good Morning $CBDW

From the October 1st news, this is perhaps one of the most impressive possibilities of the AI technology that CBDW now offers:

With its AI-powered structure prediction algorithms, this platform has the potential to revolutionize drug discovery. It can design small molecules, optimize the design of antibodies and other proteins, and even repurpose drug molecules. With a database of 19 viruses, the Sutra™ AI platform can predict and help prevent future pandemics.

The most recent news from CBDW illustrates how undervalued the current pps levels are. AI technology can multiply the power of existing assets many times over as described here:

Adnexus Biotechnologies Unveils Sutra(TM), a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research

DALLAS, TX / ACCESSWIRE / October 1, 2024 / Adnexus Biotechnologies Inc., a pioneering company in Artificial Intelligence-driven innovations for early drug discovery and infectious disease research, is pleased to announce its new AI Empowered Drug Discovery Platform, Sutra™.

https://www.accesswire.com/imagelibrary/0ba2a55f-87c0-4f57-b991-9a3a312c6109/925182/12084.png

The Sutra™ AI platform has not just confirmed decades of work, but also added new targets for monoclonal antibodies within weeks, receiving independent validation of their potential from collaborators. Adnexus Biotechnologies Inc.'s AI algorithms have identified several promising drug candidates. The company has identified a target in the mitochondrial metabolism that has a role in oncology. The company then adds them to an ever-growing IP portfolio, including patents, trademarks, and trade secrets, enhancing its competitive advantage and potential for future revenue. The success and validation of the Sutra™ AI platform for AI-discovered drugs are testaments to its capabilities and the future it promises.

Adnexus Biotechnologies Inc. is dedicated to pushing the boundaries of drug discovery with its AI Drug Discovery (AIDD) player, Sutra™. With its AI-powered structure prediction algorithms, this platform has the potential to revolutionize drug discovery. It can design small molecules, optimize the design of antibodies and other proteins, and even repurpose drug molecules. With a database of 19 viruses, the Sutra™ AI platform can predict and help prevent future pandemics. With access to a curated library of 8 million molecules, the platform makes possible the discovery of new drugs that precisely target neutralizable epitopes on viruses to enhance the potency and efficacy of existing therapies. The Sutra™ team's unwavering dedication to leveraging microbiome samples to identify new biomarkers for neurodegenerative diseases instills hope for future medical breakthroughs.

Adnexus Biotechnologies Inc. harnesses the power of AI to revolutionize drug repurposing, offering a cost-effective alternative to developing new drugs from the ground up. Drug repurposing involves identifying potential new applications for existing compounds, which can be time-consuming and labor-intensive. However, AI algorithms can analyze existing drug databases and identify potential new applications for these compounds in a fraction of the time, making it a game-changer in the pharmaceutical industry. Adnexus is exploring synergizing AI with suitable linkers between antibodies and drugs to promote multi-drug combinations. This approach will bring new therapeutics to market with more substantial impacts than combination therapies and address unmet medical needs, expediting drug discovery and regulatory approvals.

Gaurav Chandra, the CEO of Adnexus Biotechnologies Inc., stated, "Our innovative use of AI reflects a broader trend toward embracing advanced technologies to overcome traditional limitations in the biotech industry. We are very excited about our AI-empowered drug discoveries. Adnexus is proud to introduce and implement the latest Artificial Intelligence innovations in research and development technology-keeping the company at the forefront of early drug discovery and development and other revolutionary discoveries critical to treating infectious diseases."

Dr. Chandra continued, "As we advance our HIV therapeutics, we intend to offer our expertise as unique SAAS and DAAS revenue-generating models by next year. This strategic move is part of our commitment to pursuing multiple revenue-generating strategies to broaden our offerings and support academic and biotechnology companies in advancing their scientific endeavors. This commitment underscores our financial stability and growth potential."

Adnexus has recently executed a Letter of Intent with 1606 Corp (OTC PINK:CBDW), an AI technology company, for a strategic investment in the company.

About Adnexus Biotechnologies Inc.

Adnexus is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease, and neurodegenerative disease research. Its proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments. For more information, please visit https://www.adnexusbiotech.com.

Industry Information

The global market size for artificial intelligence in drug discovery was estimated at USD 1.5 billion in 2023 and is projected to grow at a CAGR of 29.7% from 2024 to 2030. The demand for AI-powered solutions in drug discovery is increasing due to the need for new drug therapies, expanded manufacturing capacities in the life sciences industry, and technological advancements. AI technologies such as machine learning and deep learning are being used at various stages of drug discovery, including initial compound screening and predicting success rates in clinical trials. Additionally, the growth of startups developing AI-powered solutions and increased investments and funding drive market expansion.

Forward-Looking Statements

This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. Adnexus does not undertake any obligation to update forward-looking statements except as required by law.

For inquiries, please get in touch with Dr. Gaurav Chandra, CEO, gaurav.chandra@adnexusbiotech.com.

https://www.adnexusbiotech.com

cbdw.ai

Contact Information

Gaurav Chandra
CEO
gaurav.chandra@adnexusbiotech.com

SOURCE: Adnexus Biotechnologies Inc.

Management commentary on the new partnership looks like this is a very good fit:

Dr. Gaurav Chandra, expressing his enthusiasm about the strategic partnership with 1606 Corp. and emphasizing its significance, stated, "We are thrilled to embark on this strategic partnership with 1606 Corp. Their commitment to leveraging AI technology aligns perfectly with our mission to drive breakthroughs in drug discovery and infectious disease treatment. This collaboration represents a significant opportunity to enhance our technological capabilities and expand the impact of our innovative solutions."

Austen Lambrecht, CEO of 1606 Corp., commented, "We are pleased to enter into this agreement with Adnexus. Their pioneering work in AI-driven drug discovery and infectious disease treatment closely aligns with our commitment to leveraging advanced AI technologies to develop high-impact solutions. This collaboration significantly advances our efforts to diversify and strengthen our technological capabilities."

The new strategic partnership with Adnexus Biotechnologies brings a lot of new capability here and also gives further validation to the business plans of both companies. The September announcement was informative and encouraging.
------------------------------------------------------------------------------------------------------------------------------------
Adnexus Biotechnologies Partners with 1606 Corp. for Strategic Investment to Revolutionize AI-Driven Drug Discovery

SEATTLE, WA / ACCESSWIRE / September 17, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606") is pleased to announce it has signed a Letter of Intent to acquire a strategic stake in Adnexus Biotechnologies Inc., a pioneering company in Artificial Intelligence-driven innovations for early drug discovery and infectious disease research.

This potential strategic investment exemplifies 1606 Corp.'s commitment to advancing its technological capabilities and expanding its reach in the AI sector. Integrating Adnexus's cutting-edge AI research and development into its portfolio underscores 1606 Corp.'s aim to impact the AI sector, healthcare, and biotechnology significantly. This collaboration has the potential to push the boundaries of what is achievable in these fields.

Adnexus Biotechnologies Inc. operates an advanced AI-driven drug discovery and development platform called SUTRA. This platform, at the forefront of technological innovation, identifies specific sites and biomarkers for infectious and neurological diseases. The AI platform has successfully produced Fully Human, Broadly Neutralizing, durable monoclonal antibodies unaffected by virus mutations. The AI platform utilizes a repository containing data on 19 viruses, a curated library of 8 million molecules, and human microbiome samples. The goal is to create robust models and make significant advancements in producing groundbreaking drugs that demonstrate effectiveness and disrupt the landscape of treatments for infectious and neurological diseases.

Adnexus Biotechnologies' CEO, Gaurav Chandra, emphasizing Adnexus' unwavering dedication to advancing the frontiers of pharmaceutical development, stated, "Adnexus Biotechnologies Inc. is committed to pushing the boundaries of pharmaceutical development through its state-of-the-art AI platform, monoclonal antibodies, and HIV capsid inhibitor. The pre-clinical results of the HIV capsid inhibitor in combating HIV, and the Fully Human Monoclonal Antibody (Clone3), have become priced assets of Adnexus Biotechnologies' therapeutic portfolio. We are confident we will advance these molecules with the dedicated efforts of our team of accomplished scientists and executives with advanced chemistry, pharmacology, and drug development expertise." This dedication instills confidence in our ability to deliver impactful solutions.

Dr. Gaurav Chandra, expressing his enthusiasm about the strategic partnership with 1606 Corp. and emphasizing its significance, stated, "We are thrilled to embark on this strategic partnership with 1606 Corp. Their commitment to leveraging AI technology aligns perfectly with our mission to drive breakthroughs in drug discovery and infectious disease treatment. This collaboration represents a significant opportunity to enhance our technological capabilities and expand the impact of our innovative solutions."

Austen Lambrecht, CEO of 1606 Corp., commented, "We are pleased to enter into this agreement with Adnexus. Their pioneering work in AI-driven drug discovery and infectious disease treatment closely aligns with our commitment to leveraging advanced AI technologies to develop high-impact solutions. This collaboration significantly advances our efforts to diversify and strengthen our technological capabilities."

In order to close, the transaction must follow standard due diligence and fulfill certain conditions detailed in the LOI. Both companies are optimistic that this strategic partnership will deliver substantial shareholder value, drive technological advancements, and foster innovation in their respective fields. We will keep our stakeholders informed about the progress and any significant developments throughout the process.

About Adnexus Biotechnologies Inc.

Adnexus is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease and neurodegenerative disease research. Its proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments. For more information, please visit https://www.adnexusbiotech.com.

About 1606 Corp.

1606 Corp. stands at the forefront of technological innovation, particularly in AI Chatbots. Our mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. We are dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.

As a visionary enterprise, 1606 Corp. equips businesses with the advanced tools they need to excel in the competitive digital landscape. Our commitment to innovation and quality positions us as a leader in the field, driving the industry forward and setting new benchmarks for success and customer satisfaction.

For more information, please visit cbdw.ai.

Industry Information

The global AI market, valued at $428 billion in 2022, is anticipated to reach $2.25 trillion by 2030, with a compound annual growth rate (CAGR) ranging from 33.2% to 38.1%. The sector is expected to employ 97 million individuals by 2025, reflecting its expansive and significant impact. This potential growth presents a compelling opportunity for investors and industry professionals interested in the AI sector.

Forward-Looking Statements

This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. Adnexus does not undertake any obligation to update forward-looking statements except as required by law.

For inquiries, please contact our CEO, Austen Lambrecht, at austen@1606corp.com.

Contact Information

Austen Lambrecht
CEO
austen@1606corp.com

SOURCE: 1606 Corp

Adnexus is a scam 

When did Adnexus become an "ISO-certified organization"?

$CBDW Founder Greg Lambrecht -"ISO partnerships play an important role in our strategy and we're aiming to secure ten partnerships by the end of 2024. These partnerships will enhance our operational efficiency, credibility, and market presence, ensuring that our products and services meet internationally recognized standards. As we continue to align with ISO-certified organizations, we’re committed to optimizing processes, improving customer satisfaction, and delivering excellence to our stakeholders."

Read more about out ISO partnerships strategy here: https://lnkd.in/gp-Gz6XE #CBDW #StrategicGrowth #ISOPartnerships #InvestorRelations #1606Corp CBDWAI

Technicals do not matter with stock scams, its either being pumped or DUMPED

Latest scam from Gaurav Chandra, Stephen Popp, and Tom Nelson.

$CBDW at a double bottom indicating a bullish reversal providing an opportunity for investors to obtain profits from a bullish rally. Long positions that accumulated will profit from a rising security price. www.cbdw.ai #AI #Chatbots